Orthocell Posts Record U.S. Monthly Sales for Remplir Nerve Wrap
Australian medtech firm Orthocell sold 92 units of its Remplir collagen nerve wrap in October 2026, marking the strongest U.S. month since the product's launch.
Orthocell Ltd., an Australian medical device manufacturer, recorded its highest single-month U.S. sales figure for its Remplir collagen nerve wrap in October 2026, moving 92 units in the market and signaling growing adoption of the FDA-cleared peripheral nerve repair device.
Remplir is engineered as a collagen-based wrap intended to support the repair and protection of peripheral nerves. Designed and produced in Australia, the device has been positioned by the company as an emerging category leader in key international markets, with the United States representing a critical commercial battleground for medtech firms operating in the nerve repair segment.
Read more Investcorp Reports $65.2B AUM at Gulf Investment Forum →
The October milestone reflects sustained commercial momentum for Orthocell in a specialized surgical market where clinician awareness and regulatory clearance are significant barriers to entry. The FDA clearance the device carries lends credibility to its adoption trajectory in the U.S., where competitive nerve repair products have long dominated hospital purchasing decisions.
For investors and analysts tracking the small-cap medtech space, consecutive gains in monthly unit volume can serve as an early indicator of whether a niche device is gaining durable traction or experiencing isolated demand spikes. Orthocell's disclosure of the October figure suggests the company views the sales trend as material enough to communicate to the market.
Continue reading at All Financial Services & Investing.
